Precise Bio, Carl Zeiss Meditec to develop biofabricated cornea transplant products
Click Here to Manage Email Alerts
Carl Zeiss Meditec and Precise Bio have partnered to develop and commercialize fabricated corneal tissue for endothelial keratoplasty and natural lenticule transplants to treat keratoconus and vision correction.
Carl Zeiss Meditec will invest in Precise Bio and fund the development of two cornea transplant products produced with Precise Bio’s 4D biofabrication platform technology while gaining worldwide commercialization rights for the products, according to a press release.
Biofabricated tissue may be used to replace diseased or damaged tissue and substitute for donor tissue by mimicking the anatomical structure and natural components of tissue. The 4D biofabrication technology allows for production of large quantities in a reproducible, quality controlled and cost-effective process, according to the release.
“This investment in Precise Bio is expected to complement our leading portfolio of cataract and corneal refractive workflow solutions,” Euan S. Thomson, PhD, president of ophthalmic devices and head of the digital business unit for Carl Zeiss Meditec, said in the release. “The technology has the potential to advance treatment options for corneal disease, as well as for elective procedures — furthering enabling optimization of patient care.”
Financial terms of the deal were not released.
Read more about
Click Here to Manage Email Alerts